Long-term safety of HSK44459 for pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests the long-term safety and effectiveness of an oral medication (HSK44459) in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. If you were in the earlier study profile, this study lets you keep taking the medication to see if it continues to help over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier HSK44459 study and taken your last dose as planned.
- You are not planning to have a lung transplant during this study.
- You have not lost more than 10% of your body weight without a clear reason in the previous study.
- You have not had cancer (other than certain skin cancers) in the last 5 years.
- You do not have a history of depression or anxiety disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This study is testing a new investigational drug called HW241045 in healthy volunteers. The main goal is to check how the drug is processed by the body and whether it is safe, which helps find the right dose for future studies.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.